Key Highlights
- Michael D. Krepps joins AI Proteins as Head of Corporate Strategy.
- Krepps brings vast biotech experience to accelerate miniprotein therapy development.
- AI Proteins aims to advance novel, high-value pharmaceutical therapies.
Source: Business Wire
Notable Quotes
- “Mike brings tremendous knowledge across the spectrum of biotech, and we are confident he will help us to fully unlock the power of our high-throughput miniprotein platform. He’s a perfect fit for our crew as we are making our innovative tech a reality and designing promising therapies to help patients.” — Dr. Chris Bahl, Founder, President, and Chief Scientific Officer at AI Proteins
- “Mike’s expertise will help us to further prioritize and determine the best path for moving these programs forward into development, and ultimately to the patients who need them.” — Noah D. Beerman, Chief Executive Officer at AI Proteins
- “I am honored to be joining the company as we continue on our mission to create groundbreaking new drugs, and I welcome the opportunity to help AI Proteins achieve its amazing potential.” — Michael D. Krepps, Head of Corporate Strategy at AI Proteins
SoHC's Take
The appointment of Michael D. Krepps as Head of Corporate Strategy at AI Proteins is a strategic move poised to propel the company forward in the biotechnology sector. With his extensive experience spanning scientific research, venture capital, and biotech management, Krepps is well-equipped to steer AI Proteins’ innovative miniprotein technology towards creating impactful therapeutic solutions. This leadership expansion signals AI Proteins’ commitment to advancing its pipeline and reinforces its position as a key player in developing novel protein-based therapies.
